ClinicalTrials.gg
RecruitingNCT06026111ENHANCEUpdated Oct 26, 2026

Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

An interventional study of High-Intensity Interval Training (HIIT) and Moderate-Intensity Continuous Training (MICT) in Lung Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Oct 26, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute — 7 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Dana-Farber Cancer Institute.

Planned enrollment
11th of 19
30 · median 33
Started
2024
the only one that year
No phase
10 of 25
4 open now
Registered
22nd of 25
by date

Among the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 22nd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

7 of the 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Lung Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this study is to examine the feasibility and effects of 12-week exercise training at different intensities among individuals with advanced lung cancer receiving immune checkpoint inhibitors.

The names of the study interventions involved in this study are:

  • High-intensity interval training (HIIT)
  • Moderate-intensity continuous training (MICT)
  • Usual care (UC)
Read the detailed description

This single-center, three-armed, pilot randomized controlled research study will assess feasibility and compare immune activities, cardiorespiratory fitness, physical function, and immunotherapy-related adverse events, and patient-reported outcomes between three groups - high-intensity exercise, moderate-intensity exercise, and usual care.

Participants in this study will be randomly assigned to one of three groups:

  • High-intensity interval training (HIIT)
  • Moderate-intensity continuous training (MICT)
  • Usual care (UC) The HIIT and the MICT groups will receive virtually supervised home-based exercise training three sessions per week for 12 weeks. The UC group will be asked not to change their baseline exercise behavior and will be offered to receive one of the exercise programs at the end of the initial 12 weeks.
03

Conditions studied

  • Lung Cancer

Browse trials for

Keywords

  • Lung Cancer
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • diagnosed with non-small cell lung cancer (NSCLC).
  • Receiving or scheduled to begin immunotherapy, as monotherapy or in combination, in the , adjuvant, or /advanced setting, with a plan to continue immunotherapy throughout the exercise intervention period (for neoadjuvant patients, throughout the planned preoperative immunotherapy course prior to surgery).
  • Medical clearance to perform exercise intervention and testing by their treating oncologist.
  • No uncontrolled medical conditions that could be exacerbated with exercise (e.g., uncontrolled hypertension or diabetes).
  • Ability to communicate and complete written forms in English.
  • Participate in less than or equal to 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month.
  • Ability to understand and the willingness to sign prior to any study-related procedures.
  • Willing to travel to DFCI main campus for necessary data collection.

Exclusion criteria

Exclusion Criteria:

  • Participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described exercise intervention, where additional exercise done regularly will contaminate the intervention outcomes.
  • Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded.
  • Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
  • Development of second (except for basal cell carcinoma or squamous cell carcinoma of the skin) that requires concurrent treatment, which would interfere with this study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    High-Intensity Interval Training (HIIT)

    Patients in the HIIT group will perform alternating vigorous-intensity and recovery aerobic exercise intervals on a provided home stationary bike. The HIIT protocol consists of alternating a high-intensity exercise phase (1 min at 65-90% of workload corresponding to VO2peak) and a recovery phase (1 min at 30%), and the high-intensity and recovery intervals will be repeated 5-10 times in each session.

    Behavioral: High-Intensity Interval Training (HIIT)

  • Experimental
    Moderate-Intensity Continuous Training (MICT)

    The MICT group will perform an aerobic exercise at a continuous intensity in each session on a stationary bike. Similar to HIIT, the intensity will be progressed (47.5-60%). The total work of MICT is equalized with HIIT for training volume and frequency to compare the differences exerted from different intensities and energy expenditure.

    Behavioral: Moderate-Intensity Continuous Training (MICT)

  • No intervention
    Usual Care (UC)

    Participants will be asked to maintain their baseline exercise behavior.

Interventions

  • BehavioralHigh-Intensity Interval Training (HIIT)

    Home-based, virtually supervised, aerobic exercise intervention at a high intensity in an interval fashion.

  • BehavioralModerate-Intensity Continuous Training (MICT)

    Home-based, virtually supervised, aerobic exercise intervention at a moderate intensity in a continuous fashion.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants completing the exercise intervention sessions

    The primary outcome is feasibility and will be assessed by the proportion of enrolled participants completing the exercise intervention sessions with \>/=70% completion considered feasible.

    Time frame: Up to 14 weeks

Secondary outcomes

  1. Neutrophil-lymphocyte ratio (NLR)

    Neutrophil-lymphocyte ratio (NLR) will be assessed as a systemic immune marker as well as a prognostic marker of immunotherapy. Mononuclear lymphocyte phenotypes will be conducted in the Immune Assessment Laboratory. Immunofluorescence assays in whole blood will identify the counts of neutrophils and lymphocytes. Fasting blood will be taken in the morning following an overnight fast. Two 10.0 mL EDTA tubes will be collected and one spun for 10 minutes at 2860rpm within one hour of collection and 1.0mL of plasma will be transferred to a secondary tube to cryovials. Samples will be stored or shipped frozen at -70°C. Samples will be centrifuged, stored at -80°C, and batch-analyzed after post-intervention assessments.

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  2. Cardiopulmonary Fitness

    Cardiorespiratory fitness will be assessed as VO2peak by a graded maximal cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 15-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms.

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  3. Muscular Strength

    Muscular strength will be measured as 1-repetition maximum (RM) (i.e., the greatest resistance that can be moved through the full range of motion), which has been the standard for strength assessments. 1-RM values will be estimated from 10-RM using validated equations on 12 exercises including the ten exercises utilized in the prescription not performed on machines.

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  4. Short Physical Performance Battery

    Physical function will be assessed by the Short Physical Performance Battery (SPPB), which includes the following 3 lower extremity measures completed in the following order. Timed balance (seconds): Balance will be assessed under 3 conditions (side-by-side, semi-tandem, and tandem stands). Gait speed (seconds): Gait speed will be assessed over a 4-meter flat surface distance. The participant will be asked to complete 2 attempts of this test. Time will be recorded using an electronic timing system. Chair stand (seconds): Chair stand will be performed under 2 conditions: a) subjects will perform a single chair stand; b) subjects will be asked to perform 5 repeated chair stands as quickly as possible; time to completion will be recorded.

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  5. Patient Reported Outcomes - Health-related quality of life

    quality of life will be assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)-C30.

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  6. Patient Reported Outcomes - Lung-cancer related quality of life

    Lung-cancer related quality of life will be assessed by the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-Lung Cancer (EORTC-QLQ-LC)-29.

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  7. Patient Reported Outcomes - Immunotherapy Symptoms

    Immunotherapy symptoms will be assessed by the MD Anderson Symptom Inventory (MDASI) Immunotherapy early-phase trials (EPT).

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  8. Patient Reported Outcomes - Anxiety and Depression

    Anxiety and Depression will be assess using the Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items, divided into two 7-item subscales (anxiety and depression). The respondent rates each item on a 4-point scale ranging from 0 (absence) to 3 (extreme presence) and the total score is out of 42 (21 per subscale).

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

  9. Patient Reported Outcomes - Sleep Quality

    Sleep will be assessed using the Pittsburg Sleep Quality Index (PSQI).

    Time frame: Baseline (Week 1) and post-intervention (Week 14)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2027, 46 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 46 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Sep 6, 2023
StartActual
Feb 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • ChangedBefore Having been receiving immunotherapy for at least one month with a plan to continue for at least 12 weeks prospectively at the time of recruitment.Now Receiving or scheduled to begin immunotherapy, as monotherapy or in combination, in the neoadjuvant, adjuvant, or metastatic/advanced setting, with a plan to continue immunotherapy throughout the exercise intervention period (for neoadjuvant patients, throughout the planned preoperative immunotherapy course prior to surgery).
  • EditedWilling to travel to DFCI main campus for necessary data collection.
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Having been receiving immunotherapy for at least one month with a plan to continue for at least 12 weeks prospectively at the time of recruitment.Now Receiving or scheduled to begin immunotherapy, as monotherapy or in combination, in the neoadjuvant, adjuvant, or metastatic/advanced setting, with a plan to continue immunotherapy throughout the exercise intervention period (for neoadjuvant patients, throughout the planned preoperative immunotherapy course prior to surgery).
    • EditedWilling to travel to DFCI main campus for necessary data collection.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06026111
Responsible party
Christina Dieli-Conwright, PhD (Principle Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Sep 6, 2023
Start date
Feb 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Christina Dieli-Conwright, PhD, MPH
Contact
christinam_dieli-conwright@dfci.harvard.edu
617-582-8321
Christina Dieli-Conwright, PhD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion